- Home
- GDHG vs RNAZ Comparison
GDHG vs RNAZ Comparison
Compare GDHG & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDHG
- RNAZ
- Stock Information
- Founded
- GDHG 2008
- RNAZ 2016
- Country
- GDHG China
- RNAZ United States
- Employees
- GDHG N/A
- RNAZ N/A
- Industry
- GDHG Services-Misc. Amusement & Recreation
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- GDHG Consumer Discretionary
- RNAZ Health Care
- Exchange
- GDHG Nasdaq
- RNAZ Nasdaq
- Market Cap
- GDHG 8.1M
- RNAZ 8.3M
- IPO Year
- GDHG 2023
- RNAZ 2021
- Fundamental
- Price
- GDHG $1.53
- RNAZ $0.37
- Analyst Decision
- GDHG
- RNAZ Strong Buy
- Analyst Count
- GDHG 0
- RNAZ 1
- Target Price
- GDHG N/A
- RNAZ $3.00
- AVG Volume (30 Days)
- GDHG 88.0K
- RNAZ 449.6K
- Earning Date
- GDHG 07-30-2024
- RNAZ 11-14-2024
- Dividend Yield
- GDHG N/A
- RNAZ N/A
- EPS Growth
- GDHG N/A
- RNAZ N/A
- EPS
- GDHG 1.62
- RNAZ N/A
- Revenue
- GDHG $25,549,903.00
- RNAZ N/A
- Revenue This Year
- GDHG N/A
- RNAZ N/A
- Revenue Next Year
- GDHG N/A
- RNAZ $100.00
- P/E Ratio
- GDHG $0.94
- RNAZ N/A
- Revenue Growth
- GDHG N/A
- RNAZ N/A
- 52 Week Low
- GDHG $1.46
- RNAZ $0.22
- 52 Week High
- GDHG $1,241.50
- RNAZ $18.68
- Technical
- Relative Strength Index (RSI)
- GDHG 31.60
- RNAZ 35.67
- Support Level
- GDHG $1.65
- RNAZ $0.31
- Resistance Level
- GDHG $2.17
- RNAZ $0.49
- Average True Range (ATR)
- GDHG 0.25
- RNAZ 0.04
- MACD
- GDHG -0.00
- RNAZ -0.01
- Stochastic Oscillator
- GDHG 7.57
- RNAZ 15.81
About GDHG Golden Heaven Group Holdings Ltd.
Golden Heaven Group Holdings Ltd is an offshore holding company. Through the operating entities in China, It manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. The parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals, circus performances, and high-tech facilities. The parks collectively contain nearly 159 rides and attractions. The firm's revenue is generated from selling access to rides and attractions, charging fees for special event rentals, and collecting regular rental payments from commercial tenants.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.